Phio Pharmaceuticals Corp.
PHIONASDAQHealthcareBiotechnology
Latest quote
$1.18
−$0.03 · -2.48%
PHIO company overview
Historical prices · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
50
Fair Value
Momentum
24
Weakening
Sentiment
67
Bullish
Risk resilience
35
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePhio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Robert L. Bitterman
- Listed since
- May 10, 2012
- Employees
- 6
Market position
- Volume
- 138.29K
- 0.29× average
- Average volume
- 469.29K
- Average daily volume
- Market cap
- 13.71M USD
- Beta
- 0.79
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -0.88×
- P/B (TTM)
- 1.09×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0×
- Altman Z-score
- -13.03
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 4.62M USD | 3.64M USD | 6.33M USD | 7.01M USD | 8.89M USD |
| Gross profit | −4.62M USD | −3.64M USD | −6.33M USD | −7.01M USD | −8.89M USD |
| Research and development | 4.62M USD | 3.64M USD | 6.33M USD | 7.01M USD | 8.89M USD |
| Selling, general, and administrative | 4.6M USD | 3.74M USD | 4.29M USD | 4.45M USD | 4.63M USD |
| Operating expenses | 4.6M USD | 3.74M USD | 4.49M USD | 4.45M USD | 4.63M USD |
| Interest income | — | 231K USD | — | — | — |
| Depreciation and amortization | 3K USD | 2K USD | 184K USD | 71K USD | 75K USD |
| Operating income | −9.22M USD | −7.39M USD | −10.82M USD | −11.46M USD | −13.51M USD |
| Net income | −8.7M USD | −7.15M USD | −10.83M USD | −11.48M USD | −13.29M USD |
Company facts updated Aug 24, 2026.
PHIO peers
ETFs holding PHIO
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research PHIOresearch.disclaimer